Komada F - Search Results

1

Regulation of CMV promoter-driven exogenous gene expression with doxorubicin in genetically modified cells.

Kinoshita A, Kobayashi D, Hibino Y, Isago T, Uchino K, Yagi K, Hirai M, Saitoh Y, Komada F. Kinoshita A, et al. Among authors: komada f. J Pharm Pharmacol. 2008 Dec;60(12):1659-65. doi: 10.1211/jpp.60.12.0012. J Pharm Pharmacol. 2008. PMID: 19000371

2

Regulation of exogenous gene expression by superoxide.

Kinoshita A, Kobayashi D, Saitoh Y, Tanabe N, Uchino K, Nishiguchi K, Okumura K, Komada F. Kinoshita A, et al. Among authors: komada f. Pharm Res. 2006 Nov;23(11):2536-41. doi: 10.1007/s11095-006-9076-4. Epub 2006 Oct 18. Pharm Res. 2006. PMID: 17048122

3

Effects of anticancer agents and scavengers on CMV-promoter-driven exogenous gene expression in genetically modified cells.

Kinoshita A, Kobayashi D, Saitoh Y, Komada F. Kinoshita A, et al. Among authors: komada f. J Pharm Pharmacol. 2009 Apr;61(4):527-31. doi: 10.1211/jpp/61.03.0016. J Pharm Pharmacol. 2009. PMID: 19298701

4

Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor.

Usui T, Saitoh Y, Komada F. Usui T, et al. Among authors: komada f. Biol Pharm Bull. 2003 Apr;26(4):510-7. doi: 10.1248/bpb.26.510. Biol Pharm Bull. 2003. PMID: 12673034 Free article.

5

Comparative study of superoxide dismutase in normal and hereditary cataract (UPL) rats.

Komada F, Saitoh Y, Kawabata H, Ohsaka N, Okumura K, Tomohiro M, Ito Y, Terao M, Hori R. Komada F, et al. Biol Pharm Bull. 2000 Dec;23(12):1536-40. doi: 10.1248/bpb.23.1536. Biol Pharm Bull. 2000. PMID: 11145194

6

Effect of mixing method on the mixing degree during the preparation of triturations.

Nakamura H, Yanagihara Y, Sekiguchi H, Komada F, Kawabata H, Ohtani M, Saitoh Y, Kariya S, Suzuki H, Uchino K, Iga T. Nakamura H, et al. Among authors: komada f. Yakugaku Zasshi. 2004 Mar;124(3):127-34. doi: 10.1248/yakushi.124.127. Yakugaku Zasshi. 2004. PMID: 15049130 Free article.

7

Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats.

Kiyohara Y, Nishiguchi K, Komada F, Iwakawa S, Hirai M, Okumura K. Kiyohara Y, et al. Among authors: komada f. Biol Pharm Bull. 1993 Nov;16(11):1146-9. doi: 10.1248/bpb.16.1146. Biol Pharm Bull. 1993. PMID: 8312873

8

Preparation and evaluation of gene-transfected cultured skin as a novel drug delivery system for severely burned skin.

Hada N, Todo H, Komada F, Sugibayashi K. Hada N, et al. Among authors: komada f. Pharm Res. 2007 Aug;24(8):1473-9. doi: 10.1007/s11095-007-9265-9. Epub 2007 Mar 22. Pharm Res. 2007. PMID: 17377741

9

Improvement in wound healing by epidermal growth factor (EGF) ointment. II. Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn.

Kiyohara Y, Komada F, Iwakawa S, Hirai M, Fuwa T, Okumura K. Kiyohara Y, et al. Among authors: komada f. J Pharmacobiodyn. 1991 Jan;14(1):47-52. doi: 10.1248/bpb1978.14.47. J Pharmacobiodyn. 1991. PMID: 1861238

10

Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF.

Okumura K, Kiyohara Y, Komada F, Iwakawa S, Hirai M, Fuwa T. Okumura K, et al. Among authors: komada f. Pharm Res. 1990 Dec;7(12):1289-93. doi: 10.1023/a:1015946123697. Pharm Res. 1990. PMID: 2128896

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page